To validate the in vivo tumor-targeting capability of [68Ga]Ga-DOTA-CCK2R-dimer, we conducted ex vivo biodistribution studies of treated AR42J tumor-bearing mice (Figure 2C-D). This evidence concerns the gene CCKBR and neoplasm.